A Review of Cardiomyopathy Gene Variants as Drivers of Early-Onset Atrial Fibrillation: Linking Genotype to Phenotype in Precision Medicine
Clicks: 23
ID: 321841
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
6.6
/100
23 views
3 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #28 of 74 articles by views in european heart journal - quality of care and clinical outcomes
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia worldwide, typically driven by age, obesity and other conventional cardiovascular risk factors. However, a subset of patients develop early-onset AF-often before 65 years of age in the absence of structural heart disease-suggesting alternative mechanisms beyond acquired risk. Emerging evidence implicates pathogenic variants in cardiomyopathy-associated genes as key drivers in this population. This review synthesises contemporary evidence linking cardiomyopathy gene variants, particularly in TTN, LMNA, MYH7, and PKP2, to early-onset AF. Across multiple sequencing cohorts, pathogenic or likely pathogenic variants are identified in 5-20% of young AF patients, with prevalence rising sharply at younger ages. TTN truncating variants confer up to a twofold increased risk of AF and a tenfold higher risk of subsequent dilated cardiomyopathy, whereas LMNA mutations are associated with aggressive atrial fibrosis, conduction disease, and early recurrence after catheter ablation. Longitudinal studies demonstrate that genotype-positive AF patients face higher risks of heart failure, sudden cardiac death, and progression to overt cardiomyopathy. These findings redefine early-onset AF as a potential sentinel manifestation of inherited myocardial disease rather than an isolated electrical disorder. Genetic testing-especially in individuals with AF onset ≤45 years or a family history of cardiomyopathy-enables early detection, cascade screening, and personalized surveillance. Integrating genomics, advanced imaging, and electrophysiologic management supports a precision medicine framework that may improve outcomes by identifying and intervening before structural disease develops.
| Reference Key |
openalex_W7170062098
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Johannes Reinhold, Paris Chrysostomou, Patrick M. Heck, David Begley, K Letsas, Kapelios Cj, CA Martin, Stephen Pettit, M. Benjamin Shoemaker, Charikleia Papadopoulou |
| Journal | european heart journal - quality of care and clinical outcomes |
| Year | 2026 |
| DOI |
10.1093/ehjqcco/qcag113
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.